Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Wyeth Research Division of Wyeth Pharmaceuticals Inc
Femme et Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical resaearch and Development
MAJ Il y a 5 ans
A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 3 Oral Doses of ERB-041 in Subjects With Rheumatoid Arthritis on a Background of Methotrexate Therapy
To compare the efficacy and the safety of 3 dose levels of oral ERB-041 administered daily for 12 weeks versus palcebo in subjects with active RA who had a suboptimal response to therapy with stable d...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc
MAJ Il y a 5 ans
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation Estudio multicéntrico, aleatorizado, en doble ciego, controlado con placebo y de grupos paralelos, de MOA-728 subcutánea para el tratamiento del estreñimiento inducido por opiáceos
Primary: To evaluate the safety, efficacy, and tolerability of subcutaneous MOA-728 versus placebo in subjects with nonmalignant pain who have opioid-induced constipation.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc
MAJ Il y a 5 ans
A Phase 2, Randomized, Open-label Study of Bosutinib Administered in Combination With Letrozole Versus Letrozole Alone as First Line Therapy in Post-Menopausal Women With Locally Advanced or Metastatic ER+/PgR+/erbB2- Breast Cancer
To compare the efficacy, in terms of PFS assessed by an independent radiology vendor, of bosutinib in combination with letrozole versus letrozole alone as first line treatment or as recurrence of adju...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc
MAJ Il y a 5 ans
A Multicenter, Randomized, Double-Blind, Comparison Study of the Safety and Efficacy of a Once-Daily Dose of Tigecycline versus Ertapenem for the Treatment of Foot Infections in Subjects with Diabetes
To compare the relative safety and clinical efficacy of a once-daily dose of tigecycline versus ertapenem in the treatment of subjects with diabetic foot infections.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc
MAJ Il y a 5 ans
A Randomized, Parallel, Double-Blind, Placebo-Controlled Dose Regimen Finding Study to Evaluate the Safety and Efficacy of TRU-015 in Subjects With Active Seropositive Rheumatoid Arthritis on a Stable Background of Methotrexate
To evaluate the clinical efficacy of two dosing regimens of TRU-015 in active seropositive RA subjects compared with placebo at 24 weeks
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
MAJ Il y a 5 ans
A Multicenter, Parallel, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly in Subjects With Moderate to Severe Plaque Psoriasis
to assess the efficacy and safety of etanercept 50 mg administered once weekly in subjects with psoriasis over 12 weeks.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
MAJ Il y a 5 ans
An Open-Label Study of the Safety and Efficacy of ReFacto AF in Previously Untreated Patients in Usual Care Settings Estudio abierto sobre seguridad y eficacia de ReFacto AF en pacientes no tratados previamente, en condiciones asistenciales habituales
The primary objective is to evaluate the safety of ReFacto AF in previously untreated patients less than 6 years of age.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc
MAJ Il y a 5 ans
Estudio fase 3, randomizado, controlado, doble ciego para evaluar la seguridad, tolerabilidad e inmunogenicidad de la Vacuna Neumocócica Conjugada 13-valente en niños sanos administrada con la vacuna Meningocóccica C conjugada a toxoide tetánico y otras vacunas de rutina del calendario vacunal en España A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain
Primary objectives: -to demonstrate that the immune response induced by NeisVac-C given with 13vPnC is noninferior to the immune response induced by NeisVac-C given with 7vPnC when measured 1 month af...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc
MAJ Il y a 5 ans
Phase 2 Study of HKI-272 in Subjects with Advanced Breast Cancer
Determine the sixteen (16) week progression-free survival (PFS) rate for HKI-272 in women with advanced breast cancer.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
MAJ Il y a 5 ans
A Multi-center, Open-label Extension Study of the Safety and Tolerability of Long-term Administration of Oral CCI-779 (Temsirolimus) in Subjects with Relapsing Multiple Sclerosis Who Completed Study 3066A2-210-WW
To evaluate the safety and tolerability of long-term therapy with 1 dose level of oral CCI-779 (temsirolimus; 8 mg/day) administered to subjects with relapsing-remitting or secondary progressive MS wi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
Suivant